US govt order to have nil impact on Indian pharma players, says Cipla

Umang Vohra of Cipla says that the US order to lower drug costs will likely target branded drugs. He believes generic drug prices are already competitive. Vohra also states that potential US tariffs on pharmaceutical imports are not expected to significantly impact Cipla's business. He mentions that discussions between the US and Indian governments are ongoing.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/CQaIBbU
via IFTTT